

Alaska Medicaid Pharmacy and Therapeutics Committee

Meeting date April 20, 2012

Frontier Building, 3601 C Street; Room 890/896

Agenda

Call in: 1-800-315-6338. Use access code 735#.

**DRAFT**

1. **Call to Order – Chair Richard Brodsky, MD** **8:00 am**
2. **Roll Call** **8:05 am**
3. **Public Comment - Local Public / Health Practitioners** (See guidelines on page 2)

The Department's method for class review are to better utilize the time of the P&T Committee. Classes shown in **Red** are **new classes** or **classes where \*\*new information exists and public testimony will be taken.** Classes shown in **Blue** will be reviewed only if **\*\*new information** is received, then **public testimony will be taken.** Classes shown in **Green**, **no changes have been noted and no public testimony will be taken.**

**\*\*New information includes: new indications or drugs, new warnings, or new head to head clinical evidence.**

4. **Public comment , discussion & vote on Red Classes**  
The Department will **review** the following **red classes** as the classes are **new or new information** exists.

Re-Review <b>Long Acting Beta Agonists</b>	Re-Review <b>Hepatitis C</b>
*Review <b>Ophthalmic Antibiotic-Steroid Combo</b>	Re-Review <b>Ophthalmic NSAIDS</b>

5. **Public comment, discussion & vote Blue Classes.** The Department **proposes no changes** to the P&T Committee's clinical recommendation in the following **blue classes unless new information** is received.

Re-Review <b>Ophthalmic Anti-Allergy Agents</b>	Re-Review <b>Topical Antivirals</b>
Re-Review <b>Ophthalmic Mast Cell Stabilizers</b>	Re-Review <b>Hepatitis B – Oral</b>
Re-Review <b>Otic Quinolones &lt;&gt; Otic Antibiotics</b>	Re-Review <b>Topical Antifungals</b>
Re-Review <b>Inhaled Steroids &lt;&gt; Glucocorticoid Inhaled</b>	

6. The Department **proposes no changes** to the P&T Committee's clinical recommendation to the following classes **as shown in green.**

Re-Review <b>Self Injectable Epinephrine</b>	Re-Review <b>Anti-Emetics</b>
Re-Review <b>Intranasal Antihistamines</b>	Re-Review <b>Leukotriene Inhibitors</b>
Re-Review <b>Nasal Steroids</b>	Re-Review <b>Short Acting Beta Agonists</b>
Re-Review <b>Low-Sedating Antihistamines</b>	Re-Review <b>COPD Inhalant Drugs</b>
Re-Review <b>Ophthalmic Quinolones &lt;&gt; Ophthalmic Antibiotics</b>	Re-Review <b>Ophthalmic Immunomodulator</b>
Re-Review <b>Ophthalmic Macrolides &lt;&gt; Ophthalmic Antibiotics</b>	Re-Review <b>Anti-Herpes Oral Medication &lt;&gt; Antivirals HSV</b>
Re-Review <b>2<sup>nd</sup> &amp; 3<sup>rd</sup> Generation Cephalosporins</b>	Re-Review <b>Anti-Fungal - Oral</b>
Re-Review <b>2<sup>nd</sup> &amp; 3<sup>rd</sup> Generation Quinolones</b>	Re-Review <b>Anti-viral - Influenza</b>
Re-Review <b>Macrolides</b>	Re-Review <b>Topical Antibiotics</b>
Re-Review <b>Anti-Migraines</b>	

7. **Break as needed** – 15 minutes
8. **Review minutes** from **April 20, 2012 meeting**
9. **Comments from Committee Members or Chair**
10. **Adjourn**

Future Meeting Dates: September 21, 2012, November 16, 2012, April 18, 2013, April 19, 2013

---

#### **GUIDELINES FOR PROVIDING COMMENT to the ALASKA P&T COMMITTEE**

1. All interested speakers are required to provide the Committee with the name of their organization, the speaker's relationship to the organization and topic area, prior to the start of the meeting.
2. The time on the agenda for each agenda item is limited. An individual's comments to the committee are limited to a maximum of three (3) minutes in total.
3. Only one speaker "slot" will be available per drug class representing a single manufacturer or interest group. Within the allowable three (3) minute time period, multiple speakers may share this "slot".
4. NO reference or information as to pricing is allowed in any comment(s). Such information will be considered reason for immediately ending the comment opportunity.
5. It is requested that comment provided in relation to specific medications be directed toward how this product is clinically superior or the specific advantage(s) it offers, new evidence/research results or synergistic outcomes which have been demonstrated.
6. Written medical information is not accepted at the P&T meeting. This is to be submitted Magellen prior to the meeting.